What is it about?
Please see uploaded file.
Featured Image
Read the Original
This page is a summary of: High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial, Diabetes Care, April 2025, American Diabetes Association,
DOI: 10.2337/dc24-2425.
You can read the full text:
Contributors
The following have contributed to this page
